Suppr超能文献

双去水半乳糖醇治疗晚期非鳞状宫颈癌的II期评估。一项妇科肿瘤学组研究。

Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma. A Gynecologic Oncology Group study.

作者信息

Stehman F B, Blessing J A, Homesley H D, Currie J L, Yordan E L

出版信息

Invest New Drugs. 1984;2(3):331-3. doi: 10.1007/BF00175387.

Abstract

In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m2/wk with escalation to 75 mg/m2/wk if there were no adverse effects. Twenty-seven patients were evaluable for toxicity and response. There was one complete response and one partial response. Adverse effects were not infrequent but tolerable.

摘要

在一项正在进行的II期评估中,对28例晚期或复发性宫颈非鳞状细胞癌患者静脉注射了双去水半乳糖醇(NSC 132313)。初始剂量为60mg/m²/周,如果没有不良反应则增至75mg/m²/周。27例患者可评估毒性和反应。有1例完全缓解和1例部分缓解。不良反应并不罕见,但可以耐受。

相似文献

引用本文的文献

1
Chemotherapy for advanced or recurrent carcinoma of the cervix.晚期或复发性宫颈癌的化疗
Curr Oncol Rep. 2001 Jan;3(1):33-40. doi: 10.1007/s11912-001-0040-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验